Litcius/Paper detail

γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial

Andrew J. Cowan, Margot J. Pont, Blythe Sather, Cameron J. Turtle, Brian G. Till, Edward N. Libby, David G. Coffey, Sherilyn A. Tuazon, Brent L. Wood, Ted Gooley, Vicky Q Wu, Jenna Voutsinas, Xiaoling Song, Mazyar Shadman, Jordan Gauthier, Aude G. Chapuis, Filippo Milano, David G. Maloney, Stanley R. Riddell, Damian J. Green

2023The Lancet Oncology98 citationsDOIOpen Access PDF

Topics & Concepts

Chimeric antigen receptorMedicineMultiple myelomaAntigenInternal medicineOncologyBone marrowImmunotherapyImmunologyPharmacologyCancerCancer researchCAR-T cell therapy researchMultiple Myeloma Research and TreatmentsImmunotherapy and Immune Responses
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial | Litcius